Stay updated on Nivolumab Plus Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.
Latest updates to the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedAdded new Locations and regional entries (Australian Capital Territory, New South Wales, Northern Territory, Queensland, South Australia, Tasmania, Victoria, Western Australia, Rhineland-palladium, Greater London, Tyne and Wear) to the study page. Removed HHS Vulnerability Disclosure, Melanoma, MedlinePlus Genetics, and several location groupings (Australian Capital Territory Locations, New South Wales Locations, Northern Territory Locations, Queensland Locations, South Australia Locations, Tasmania Locations, Victoria Locations, Western Australia Locations, Rhineland-palladium Locations, Greater London Locations, Tyne and Wear Locations) with an updated revision tag.SummaryDifference0.7%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Melanoma to related topics and a Related Topics link to MedlinePlus Genetics on the Study Details page. These are minor contextual enhancements that do not change the primary trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check33 days agoChange DetectedPublications section now states that PubMed-derived publications are automatically filled from PubMed, and the page revision is updated to v3.3.2, with related-topic wording removed.SummaryDifference0.1%
- Check40 days agoChange DetectedAdded Melanoma and related topics: MedlinePlus Genetics; removed government funding lapse notice on NIH operations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check47 days agoChange DetectedThe related topics section no longer lists Melanoma and MedlinePlus Genetics.SummaryDifference0.1%
- Check54 days agoChange DetectedNo additions or deletions detected; the page content and structure appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
Stay in the know with updates to Nivolumab Plus Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.